🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A3.1 Patient advocates have had a growing impact on patient care. From receiving a diagnosis, to helping push for the best treatment plan, to dealing with healthcare systems, advocates have become a more integral part of some patient journeys. #PancChat

A4.1 Social media has allowed for information to be readily available to patients and has enabled patients to connect and hear from researchers and physicians all over the world. #PancChat

A4.2 Researchers also have the experience of hearing what is happening in the pancreatic cancer community and benefit from firsthand patient experiences, offering them a different perspective.

A4.3 The overall increase in awareness has helped expand the pool of patients who are able to participate in clinical trials and increased health equity. As patients have more access to information digitally, certain barriers to care have decreased. #PancChat

A4.4 The Lustgarten Equity, Accessibility, and Diversity (LEAD) Project was also created to address discrepancies in clinical trial participation by increasing the recruitment and retention of underrepresented groups in pancreatic cancer clinical trials. #PancChat

A6.1 Lustgarten has seen exciting progress across all our priority areas of research. Early detection efforts have greatly increased the ability to identify & track high-risk individuals, including genetic testing becoming standard of care for newly diagnosed patients. #PancChat

A6.2 Patients diagnosed through the Lustgarten funded Cancer of the Pancreas Screening Study (CAPS), created for those considered at high risk for pancreas cancer, have a 5-year survival rate of 73%, compared to 44% for those diagnosed early outside of the CAPS program. #PancChat

6.3 Personalized medicine has also seen positive breakthroughs over the last 9 years, such as an increase in clinical trials for immunotherapy and the clinical testing of patient-derived organoids as a potential means to personalize pancreas cancer treatment. #PancChat

A6.4 Therapeutic development of new drugs and treatments is also a priority for Lustgarten, and tremendous efforts have been made to accelerate preclinical and clinical testing of novel drugs and combinations in pancreatic cancer. #PancChat

A7.1 A notable change in treatment approach and precision medicine is genetic testing becoming standard of care. #PancChat

A7.2 Treatments can then be personalized for some identified mutations. Patients with BRCA and related mutations also have other treatment options such as platinum-based chemotherapy or PARP inhibitors. #PancChat

A7.3 There have been advancements in targeted KRAS therapies for patients with KRAS mutations, which are present in about 90% of patients with pancreatic adenocarcinomas. #PancChat

A8.1 Awareness about pancreas cancer has increased across the board, thanks in part to efforts like #PancChat. This increase in awareness has strengthened efforts to reach more people than ever before and give a higher standard of care to a wider range of patients. #PancChat

A8.2 The NCCN guidelines now include germline screening for mutations after pancreas cancer diagnosis, to help inform risk for family members. High-risk individuals now have more opportunities to be informed and followed by health care professionals. #PancChat

A8.3 Lustgarten has built on the impact of increased awareness about early detection and risk factors through the CAPS study, which is a surveillance study for individuals who have a family history of the disease or certain genetic mutations. #PancChat

A9.1 As a research organization, #PancChat has provided Lustgarten with an opportunity to connect with and hear from patients, caregivers, advocates, that is not necessarily typical to the organization’s focus. #PancChat

A9.2 Listening to stories from people across the pancreatic cancer community has helped Lustgarten be more grounded, focused, and inspired about the work needed to transform pancreatic cancer into a curable disease. #PancChat

A9.3 Additionally, having an opportunity to collaborate with other organizations and   researchers/physicians through this platform has been an enriching and enjoyable experience. #PancChat

A10.1 Going forward, Lustgarten will continue to fund high-risk, high-reward research that focuses mainly on early detection, personalized medicine, and therapeutic development. These efforts offer tremendous hope and promise for a cure. #PancChat

A10.2 Lustgarten knows it is an exciting time in pancreas cancer research and that the research community is on the precipice of incredible, life-changing breakthroughs for all patients. #PancChat